126 related articles for article (PubMed ID: 36191155)
1. Knockout of NRF2 triggers prostate cancer cells death through ROS modulation and sensitizes to cisplatin.
Mancini MCS; Morelli AP; Severino MB; Pavan ICB; Zambalde ÉP; Góis MM; Silva LGSD; Quintero-Ruiz N; Romeiro CF; Dos Santos DFG; Bezerra RMN; Simabuco FM
J Cell Biochem; 2022 Dec; 123(12):2079-2092. PubMed ID: 36191155
[TBL] [Abstract][Full Text] [Related]
2. Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells.
Pettazzoni P; Ciamporcero E; Medana C; Pizzimenti S; Dal Bello F; Minero VG; Toaldo C; Minelli R; Uchida K; Dianzani MU; Pili R; Barrera G
Free Radic Biol Med; 2011 Oct; 51(8):1610-8. PubMed ID: 21816220
[TBL] [Abstract][Full Text] [Related]
3. Differential response of DU145 and PC3 prostate cancer cells to ionizing radiation: role of reactive oxygen species, GSH and Nrf2 in radiosensitivity.
Jayakumar S; Kunwar A; Sandur SK; Pandey BN; Chaubey RC
Biochim Biophys Acta; 2014 Jan; 1840(1):485-94. PubMed ID: 24121106
[TBL] [Abstract][Full Text] [Related]
4. Nrf2 sensitizes prostate cancer cells to radiation via decreasing basal ROS levels.
Liu M; Yao XD; Li W; Geng J; Yan Y; Che JP; Xu YF; Zheng JH
Biofactors; 2015; 41(1):52-7. PubMed ID: 25728635
[TBL] [Abstract][Full Text] [Related]
5. Continuous activation of Nrf2 and its target antioxidant enzymes leads to arsenite-induced malignant transformation of human bronchial epithelial cells.
Yang X; Wang D; Ma Y; Xu X; Zhu Z; Wang X; Deng H; Li C; Chen M; Tong J; Yamanaka K; An Y
Toxicol Appl Pharmacol; 2015 Dec; 289(2):231-9. PubMed ID: 26420645
[TBL] [Abstract][Full Text] [Related]
6. Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance.
Mirzaei S; Mohammadi AT; Gholami MH; Hashemi F; Zarrabi A; Zabolian A; Hushmandi K; Makvandi P; Samec M; Liskova A; Kubatka P; Nabavi N; Aref AR; Ashrafizadeh M; Khan H; Najafi M
Pharmacol Res; 2021 May; 167():105575. PubMed ID: 33771701
[TBL] [Abstract][Full Text] [Related]
7. p62 promotes proliferation, apoptosis‑resistance and invasion of prostate cancer cells through the Keap1/Nrf2/ARE axis.
Jiang G; Liang X; Huang Y; Lan Z; Zhang Z; Su Z; Fang Z; Lai Y; Yao W; Liu T; Hu L; Wang F; Huang H; Liu L; Jiang X
Oncol Rep; 2020 May; 43(5):1547-1557. PubMed ID: 32323805
[TBL] [Abstract][Full Text] [Related]
8. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
9. The role of the Nrf2/GSH antioxidant system in cisplatin resistance in malignant rhabdoid tumours.
Hannon Barroeta P; O'Sullivan MJ; Zisterer DM
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8379-8391. PubMed ID: 37079050
[TBL] [Abstract][Full Text] [Related]
10. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
Roh JL; Kim EH; Jang H; Shin D
Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
[TBL] [Abstract][Full Text] [Related]
11. Hypermethylation of the Keap1 gene inactivates its function, promotes Nrf2 nuclear accumulation, and is involved in arsenite-induced human keratinocyte transformation.
Wang D; Ma Y; Yang X; Xu X; Zhao Y; Zhu Z; Wang X; Deng H; Li C; Gao F; Tong J; Yamanaka K; An Y
Free Radic Biol Med; 2015 Dec; 89():209-19. PubMed ID: 26409248
[TBL] [Abstract][Full Text] [Related]
12. Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway.
Wu S; Zhang T; Du J
Drug Des Devel Ther; 2016; 10():3471-3481. PubMed ID: 27822011
[TBL] [Abstract][Full Text] [Related]
13. Induction of monoamine oxidase A-mediated oxidative stress and impairment of NRF2-antioxidant defence response by polyphenol-rich fraction of Bergenia ligulata sensitizes prostate cancer cells in vitro and in vivo.
Ghosh S; Dutta N; Banerjee P; Gajbhiye RL; Sareng HR; Kapse P; Pal S; Burdelya L; Mandal NC; Ravichandiran V; Bhattacharjee A; Kundu GC; Gudkov AV; Pal M
Free Radic Biol Med; 2021 Aug; 172():136-151. PubMed ID: 34097996
[TBL] [Abstract][Full Text] [Related]
14. Nrf2 activation protects auditory hair cells from cisplatin-induced ototoxicity independent on mitochondrial ROS production.
Zhang W; Xiong H; Pang J; Su Z; Lai L; Lin H; Jian B; He W; Yang H; Zheng Y
Toxicol Lett; 2020 Oct; 331():1-10. PubMed ID: 32428544
[TBL] [Abstract][Full Text] [Related]
15. Co-targeting autophagy and NRF2 signaling triggers mitochondrial superoxide to sensitize oral cancer stem cells for cisplatin-induced apoptosis.
Praharaj PP; Singh A; Patra S; Bhutia SK
Free Radic Biol Med; 2023 Oct; 207():72-88. PubMed ID: 37423560
[TBL] [Abstract][Full Text] [Related]
16. NRF2 modulation in TRAMP mice: an in vivo model of prostate cancer.
Marzioni D; Mazzucchelli R; Fantone S; Tossetta G
Mol Biol Rep; 2023 Jan; 50(1):873-881. PubMed ID: 36335520
[TBL] [Abstract][Full Text] [Related]
17. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling.
Wang N; Song L; Xu Y; Zhang L; Wu Y; Guo J; Ji W; Li L; Zhao J; Zhang X; Zhan L
EBioMedicine; 2019 Sep; 47():65-77. PubMed ID: 31495720
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism.
Yang Y; Deng Y; Chen X; Zhang J; Chen Y; Li H; Wu Q; Yang Z; Zhang L; Liu B
Toxicol Lett; 2018 Oct; 295():88-98. PubMed ID: 29857117
[TBL] [Abstract][Full Text] [Related]
19. Activation of the NRF2-ARE signalling pathway by the Lentinula edodes polysaccharose LNT alleviates ROS-mediated cisplatin nephrotoxicity.
Chen Q; Peng H; Dong L; Chen L; Ma X; Peng Y; Dai S; Liu Q
Int Immunopharmacol; 2016 Jul; 36():1-8. PubMed ID: 27093515
[TBL] [Abstract][Full Text] [Related]
20. Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia.
Syu JP; Chi JT; Kung HN
Oncotarget; 2016 Mar; 7(12):14659-72. PubMed ID: 26894974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
